PA5-53990

antibody from Invitrogen Antibodies

Targeting: EOGT AER61, C3orf64, FLJ33770

Western blot

Immunohistochemistry

Antibody data

Submit

Validation data

Product number: PA5-53990 - Provider product page
Provider: Invitrogen Antibodies
Product name: EOGT Polyclonal Antibody
Antibody type: Polyclonal
Antigen: Recombinant full-length protein
Description: Immunogen sequence: NEAPPNTHSI PGEPLYNYAS IRLPEEHIPF FLHNNRHIAT VCRKDSLCPY KKHLEKLKYC WGYEKSCKPE FRFGYPVCSY VDMGWTDTLE SAEDIFWKQA DFGYARERLE EMHVLCQPKE TSDSSLVCSR YLQ Highest antigen sequence identity to the following orthologs: Mouse - 74%, Rat - 74%.
Reactivity: Human
Host: Rabbit
Isotype: IgG
Vial size: 100 µL
Concentration: 0.1 mg/mL
Storage: Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

EOGT protein structure - PA5-53990 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 High-EOGT expression was associated with tumor staging, including TNM stage (A) , grade (B) , and stage (C) . (D) Correlation of EOGT expression with PECAM1 (CD31). (E) Immunofluorescent staining of EOGT (red), CD31 (green), and DAPI (blue) in normal liver tissues, T1 stage HCC tissues, and T3 stage HCC tissues. (F) Immunofluorescent staining of EOGT (red) and DAPI (blue) in HCC tissue. (G) Quantification of EOGT-positive signal in normal liver tissues ( n = 72), T1-2 stage HCC tissues ( n = 41), and T3-4 stage HCC tissues ( n = 26). Values represent mean +- SEM expressed as arbitrary units (AU) of EOGT-positive area normalized by total tumor area. (H) Quantification of EOGT normalized by CD31 (EOGT/CD31) in T1-2 stage HCC tissues ( n = 41) and T3-4 stage HCC tissues ( n = 26). (I) Quantification of CD31-positive signal in normal liver tissues ( n = 72), T1-2 stage HCC tissues ( n = 41), and T3-4 stage HCC tissues ( n = 26). Values represent mean +- SEM expressed as arbitrary units (AU) of CD31-positive area normalized by total tumor area (* P < 0.05, *** P < 0.001).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 8 Analysis of immune cell infiltration in HCC. (A) EOGT expression was highly expressed on different immune cell subsets according to single-cell RNA-sequencing results of six HCC patients. (B) Immunofluorescent staining of EOGT (red), CD11c (green), CD19 (green), CD68 (green), and DAPI (blue) in HCC tissue. (C) Correlations of EOGT expression with immunosuppressive molecules (PD-L1, PD-1, CTLA4, and HAVCR2) involved in T-cell exhaustion. (D) Correlations of EOGT expression with markers of immunosuppressive cells (MDSCs, TAMs, and Tregs).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 9 Differences of immune scores (A) and stromal scores (B) between EOGT-low and EOGT-high expression subgroups. (C, D) KM survival curve of OS based on immune scores, stromal scores, and EOGT expression levels. L and H, respectively, represented the low-EOGT and high-EOGT expression groups. LIS and HIS, respectively, represented low-immune scores group and high-immune scores group. LSS and HSS, respectively, represented low-stromal scores group and high-stromal scores group. (E) Twenty-two tumor-infiltrating immune cells in HCC samples were estimated using the CIBERSORT algorithm. (F) The proportion of 22 tumor-infiltrating immune cells in HCC samples with high- and low-EOGT expression. (G) KM curves of OS in HCC samples based on EOGT expression and the levels of tumor-infiltrating CD8 + T cells. (H) Immunofluorescent staining of EOGT (red), CD8 (green), and DAPI (blue) in HCC tissues (* P < 0.05, ** P < 0.01, **** P < 0.0001).